International Drug Policy Consortium

International Drug Policy Consortium
Name	International Drug Policy Consortium
Formation	2006
Type	Non-governmental organization
Headquarters	London
Region served	International

International Drug Policy Consortium The International Drug Policy Consortium is a global network of non-governmental organizations, think tanks, and experts focused on drug policy reform and public health. It engages with stakeholders including United Nations Office on Drugs and Crime, World Health Organization, Amnesty International, Human Rights Watch, and regional bodies to influence international frameworks such as the Single Convention on Narcotic Drugs and the United Nations General Assembly Special Session on the World Drug Problem. The consortium provides research, advocacy, and technical assistance to actors involved in debates in forums like the European Union, the Organization of American States, the African Union, and national parliaments including the United Kingdom Parliament and the United States Congress.

History

The consortium was established in 2006 following meetings between civil society actors such as Harm Reduction International, Transform Drug Policy Foundation, Médecins du Monde, Open Society Foundations, and academic institutions including London School of Economics and Global Commission on Drug Policy members. Early activities connected to major events like the UN General Assembly Special Session on the World Drug Problem (2016) and precedents including the 1961 Single Convention on Narcotic Drugs and the 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Over time the network expanded through partnerships with regional coalitions active in contexts such as the Andean Community, Association of Southeast Asian Nations, and the Caribbean Community.

Mission and Objectives

The consortium’s stated mission aligns with agendas promoted by organizations such as United Nations Development Programme, Pan American Health Organization, Global Fund to Fight AIDS, Tuberculosis and Malaria, and the World Bank: promoting evidence-based, humane drug policies that respect human rights. Objectives reference collaboration with actors like judicial systems in countries influenced by treaties including the 1961 Single Convention on Narcotic Drugs and align with recommendations from panels such as the Global Commission on Drug Policy. It emphasizes policy reform in line with instruments like the Universal Declaration of Human Rights and engages with advocacy models practiced by Amnesty International and Human Rights Watch.

Structure and Governance

The consortium operates as a networked secretariat based in London with governance mechanisms involving an international board comprised of representatives from organizations such as Transform Drug Policy Foundation, Harm Reduction International, Open Society Foundations, and universities including University College London and Columbia University. Decision-making is influenced by convenings similar to those held by The Lancet commissions and modelled on coordination seen in coalitions like the Stop TB Partnership and the Global Network of People Living with HIV. Funding has been received from philanthropic entities such as Open Society Foundations and foundations that commonly support public health networks.

Policy Work and Areas of Focus

Policy work covers harm reduction strategies advocated by Harm Reduction International and public health approaches promoted by World Health Organization guidelines, including syringe exchange, opioid substitution treatment, and decriminalization models championed by the Global Commission on Drug Policy. The consortium addresses international law instruments like the Single Convention on Narcotic Drugs (1961), engages in treaty reform debates similar to those around the International Narcotics Control Board, and monitors enforcement practice in jurisdictions from Portugal and Uruguay to Thailand and Mexico. Its focus intersects with topics pursued by UNAIDS, Human Rights Watch, and legal reforms considered in bodies like the Inter-American Commission on Human Rights.

Publications and Research

The consortium publishes reports, briefing papers, and analysis comparable in scope to outputs from Chatham House, BRICS Policy Center, and academic journals such as The Lancet and International Journal of Drug Policy. Research topics include comparative law analyses referencing cases from the European Court of Human Rights, epidemiological reviews in line with World Health Organization methods, and policy evaluations akin to those produced by RAND Corporation and Institute for Policy Studies. It also issues policy briefs before major events including sessions of the United Nations Commission on Narcotic Drugs and the UN General Assembly Special Session on the World Drug Problem (2016).

Advocacy, Campaigns, and Partnerships

Advocacy campaigns have engaged coalitions and partners such as Open Society Foundations, Médecins Sans Frontières, Amnesty International, Human Rights Watch, and regional civil society networks in Latin America, Asia, and Africa, connecting with policy moments like the UN General Assembly Special Session on the World Drug Problem (2016). The consortium works in alliance with research institutions such as London School of Hygiene & Tropical Medicine and Johns Hopkins Bloomberg School of Public Health and collaborates with treaty actors like the United Nations Office on Drugs and Crime to promote alternatives to punitive approaches exemplified by reforms in Portugal and Uruguay.

Criticism and Controversies

Criticism has come from conservative policymakers, advocacy groups, and media outlets that align with prohibitionist positions seen in debates in the United States Congress, certain European Parliament factions, and law enforcement bodies such as national police unions. Controversies mirror disputes around organizations like the Global Commission on Drug Policy and center on issues of funding transparency, perceived influence by foundations such as Open Society Foundations, and disagreements over models of decriminalization versus legalization as witnessed in debates in Mexico and Canada.

Category:Drug policy organizations Category:Non-governmental organizations